ACTRN12620001307998尚未招募未知
A Prospective Photographic Analysis Of Psoriasis Severity Following Treatment With Tildrakizumab
Samson Clinical Pty Ltd0 个研究点目标入组 30 人开始时间: 2020年12月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •i) Adults (aged 18 years and above) who are eligible for systemic therapy or phototherapy.
- •ii) Moderate to severe plaque psoriasis with a PASI equal 15 and BSA equal 10%
- •iii) Minimum diagnosis of 6 months prior to Baseline
- •iv) Active plaque psoriasis present for at least 6 months from initial diagnosis
- •v) Failed to achieve an adequate response based on PASI assessment, contraindicated or intolerant to at least 3 of 4 systemic treatments for plaque psoriasis.
排除标准
- •i) Previous/current treatment with IL23.
- •ii) Previous exposure to other biologics agents
- •iii) Diagnosis of other forms of psoriasis other than plaque psoriasis
- •iv) Pregnant or lactating women (Female participants who are pregnant, planning a pregnancy or nursing a child or not on an acceptable and highly effective birth control method)
研究者
相似试验
已完成
不适用
Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab (Study P05047)PsoriasisNCT00749398Merck Sharp & Dohme LLC133
进行中（未招募）
不适用
Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of CarePsoriasisNCT04780516AbbVie141
尚未招募
不适用
An Assessment of the Prevalence of Psoriasis in Patients with Hepatitis Cchronic skin disease with increased keratinizationpsoriasis10011063NL-OMON34745Academisch Medisch Centrum80
已完成
不适用
Association between Psoriasis and gum diseasesCTRI/2018/04/013475DEPARTMENT OF SCIENCE AND TECHNOLOGY CHANDIGARH84
进行中（未招募）
不适用
Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in GreeceModerate Plaque PsoriasisModerate PsoriasisPsoriasisNCT06247319AbbVie250